Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
暂无分享,去创建一个
[1] Jeffrey A Jones,et al. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non‐Hodgkin's lymphoma , 2014, American journal of hematology.
[2] W. Wilson,et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. , 2013, Blood.
[3] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[4] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[5] C. Flowers,et al. Using primary site as a predictor of survival in mantle cell lymphoma , 2013, Cancer.
[6] Sonali M. Smith,et al. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA , 2013, Leukemia & lymphoma.
[7] G. Salles,et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.
[8] J. Drach,et al. Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study , 2012 .
[9] A. D. Van den Abbeele,et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.
[10] L. Staudt,et al. Pathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies , 2012, Immunological reviews.
[11] A. Rosenwald,et al. The complex landscape of genetic alterations in mantle cell lymphoma. , 2011, Seminars in cancer biology.
[12] M. Czuczman,et al. Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response , 2011, British journal of haematology.
[13] A. Rosenwald,et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. , 2011, Blood.
[14] M. Amiot,et al. ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents , 2011, Clinical Cancer Research.
[15] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[16] John D. Roberts,et al. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms , 2011, Clinical Cancer Research.
[17] A. Wiestner,et al. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.
[18] R. Ulrich,et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma , 2010 .
[19] L. Staudt,et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. , 2010, Blood.
[20] Michael L. Wang,et al. Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.
[21] G. Mulligan,et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial , 2010, Leukemia & lymphoma.
[22] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[23] Thomas S. Lin,et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Byrd,et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Calaminici,et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. , 2009, Blood.
[26] B. Coiffier,et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Renata Walewska,et al. Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma* , 2009, Molecular & Cellular Proteomics.
[28] E. Kimby,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[29] C. Flowers,et al. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma , 2008, Bone Marrow Transplantation.
[30] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[31] C. Doglioni,et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. , 2008, Blood.
[32] J. Raemaekers,et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] S. Alkan,et al. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. , 2006, Leukemia research.
[34] J. Leonard,et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Gascoyne,et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] E. Jaffe,et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.
[37] S. Jagannath,et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.
[38] A. Zelenetz,et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] E. Hoster,et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.
[40] G. Mcmahon,et al. VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.
[41] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Leonard,et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.